TIZIANA LIFE SCIENCES LTD (TLSA) Stock Price & Overview
NASDAQ:TLSA • BMG889121031
Current stock price
The current stock price of TLSA is 1.15 USD. Today TLSA is down by -2.54%. In the past month the price decreased by -5.74%. In the past year, price increased by 7.48%.
TLSA Key Statistics
- Market Cap
- 144.774M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
TLSA Stock Performance
TLSA Stock Chart
TLSA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to TLSA. When comparing the yearly performance of all stocks, TLSA is a bad performer in the overall market: 81.21% of all stocks are doing better.
TLSA Earnings
TLSA Forecast & Estimates
7 analysts have analysed TLSA and the average price target is 8.16 USD. This implies a price increase of 609.57% is expected in the next year compared to the current price of 1.15.
TLSA Groups
Sector & Classification
TLSA Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TLSA Ownership
TLSA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.92 | 367.796B | ||
| AMGN | AMGEN INC | 15.32 | 189.224B | ||
| GILD | GILEAD SCIENCES INC | 15.73 | 172.517B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.59 | 110.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 79.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.79 | 42.718B | ||
| INSM | INSMED INC | N/A | 33.416B | ||
| NTRA | NATERA INC | N/A | 27.358B | ||
| BIIB | BIOGEN INC | 10.94 | 25.385B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.76 | 25.059B | ||
| MRNA | MODERNA INC | N/A | 20.21B | ||
| INCY | INCYTE CORP | 12.34 | 19.119B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.11B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TLSA
Company Profile
Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in developing therapies for neurodegenerative and lung diseases. The Company’s clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Alzheimer’s, and ALS. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti-IL-6R mAb (TZLS-501), a fully human mAb, binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune and cancer, reducing circulating levels of the IL-6 cytokine. Its oncology product candidate, Milciclib, is a combination therapy for the treatment of refractory solid tumors (being cancers which are non-responsive or become resistant to treatment), especially non-small cell lung cancer (NSCLC).
Company Info
IPO: 2018-11-20
TIZIANA LIFE SCIENCES LTD
3rd Floor, 11-12 St. James's Square
London SW1Y 4LB GB
CEO: Kunwar Shailubhai
Employees: 9
Phone: 442074952379
TIZIANA LIFE SCIENCES LTD / TLSA FAQ
What does TLSA do?
Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in developing therapies for neurodegenerative and lung diseases. The Company’s clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Alzheimer’s, and ALS. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti-IL-6R mAb (TZLS-501), a fully human mAb, binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune and cancer, reducing circulating levels of the IL-6 cytokine. Its oncology product candidate, Milciclib, is a combination therapy for the treatment of refractory solid tumors (being cancers which are non-responsive or become resistant to treatment), especially non-small cell lung cancer (NSCLC).
Can you provide the latest stock price for TIZIANA LIFE SCIENCES LTD?
The current stock price of TLSA is 1.15 USD. The price decreased by -2.54% in the last trading session.
Does TIZIANA LIFE SCIENCES LTD pay dividends?
TLSA does not pay a dividend.
What is the ChartMill rating of TIZIANA LIFE SCIENCES LTD stock?
TLSA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
On which exchange is TLSA stock listed?
TLSA stock is listed on the Nasdaq exchange.
What is the market capitalization of TLSA stock?
TIZIANA LIFE SCIENCES LTD (TLSA) has a market capitalization of 144.77M USD. This makes TLSA a Micro Cap stock.
What is the Short Interest ratio of TIZIANA LIFE SCIENCES LTD (TLSA) stock?
The outstanding short interest for TIZIANA LIFE SCIENCES LTD (TLSA) is 2.12% of its float.